



# ImmunoPDT

## A Painless, Precise Breakthrough in Prostate Cancer Care



### The Challenge

- 1.4 million men diagnosed annually; 375,000 die each year.
- Current treatments—surgery, radiation, hormone therapy—often cause lifelong incontinence, impotence, and other severe side effects.
- 35% relapse after treatment; options for Biochemical Relapse (BCR) are limited to palliative care.
- Active surveillance avoids harm initially, but men risk progression and suffer psychological distress.



### The Solution – ImmunoPDT

A world-first, no-harm immunotherapy that targets only cancer cells and activates the body's own immune system to fight prostate cancer long-term.

#### Key Features

- **Targets only cancer cells** – protects healthy tissue.
- **Activates a lasting immune response** – reduces recurrence risk.
- **Walk-in, walk-out** – no anaesthesia, no recovery downtime.
- **No incontinence, impotence, or pain.**
- **10% of the cost** of current gold-standard treatments.
- **Safe for elderly, frail, and previously untreatable patients.**

**Unique Prostate Cancer control**  
**World first Immunotherapy creation**  
**All other therapies harm the patient**  
**1<sup>st</sup> Results to improve at 10 Year Follow Up**

### Groundbreaking Clinical Results

#### Phase I – 10–12 Year Follow-Up

>70% survival in both primary and relapsed patients.

Stable PSA for up to 23 years.

No deterioration in urinary, bowel, or sexual function.

#### Phase II – Ongoing

71% of patients have stable or improving cancer status.

No systemic toxicity or sun sensitivity.

Can combine safely with surgery or radiotherapy.

### How It Works

#### Day 1

A safe, plant-derived liquid chlorophyll is taken as a mouthwash; attaches to sugar and enters cancer cells.

#### Day 2

Gentle light activates the agent, destroying cancer cells without harming healthy tissue.

#### Course

12 painless sessions over 4–6 weeks.

## A Paradigm Shift in Prostate Cancer Treatment

[www.immunopdt.com](http://www.immunopdt.com)



## The Unique, Game Changer



### The Big Breakthrough

Unlike conventional treatments, ImmunoPDT trains the immune system to recognise and destroy cancer cells. In BCR patients—who normally face a rapid decline—74% were alive and well after 16 years on average.

### Market Impact & Opportunity

- Global market: USD 13.7B (2023) → USD 28.5B by 2032 (8.4% CAGR).
- Up to 60% of new diagnoses are on active surveillance—an enormous untapped treatment pool.
- First no-harm treatment for BCR.
- Low-cost delivery makes it viable for both developed and developing countries.



### Why It's Low-Risk & High-Reward

- Backed by over 1,000 treatment cycles with no severe harms.
- Patents granted in Australia, with the US and more pending.
- Nearly \$50 million already invested in R&D, trials, and manufacturing readiness.
- Fast FDA trial pathway – potential market approval within 2–3 years of trial start.

### Investment Snapshot

- Seeking AUD 25M for 20% ownership.
- R&D rebates boost spend power by 48%.
- Conservative valuation of USD 240M premarket for ~30% of the addressable market.
- Exit via trade sale or IPO expected within 3–4 years.



## A Paradigm Shift in Prostate Cancer Treatment